论文部分内容阅读
目的 :观察参麦注射液对降低进展期胃癌术后辅助化疗毒副作用的疗效。方法 :75例进展期胃癌术后患者分为两组 :单纯 EAP方案化疗组 (对照组 ) 30例及 EAP化疗并参麦液组 45例 ,化疗前及化疗后每周检查血常规、肝功能、心电图 ,观察胃肠道反应并进行 Karnofsky评分。结果 :化疗并参麦组患者外周血白细胞、血小板降低程度 ,心电图异常情况及胃肠道副作用明显低于化疗对照组 (P<0 .0 1) ,而 Karnofsky评分却明显高于对照组 (P<0 .0 5 )。结论 :参麦注射液可明显减轻和预防 EAP方案对进展期胃癌术后辅助化疗所产生的骨髓抑制、心脏毒性及消化道反应 ,从而提高患者对化疗毒副作用的耐受性及化疗期间生活质量。
Objective: To observe the efficacy of Shenmai injection in reducing the side effects of adjuvant chemotherapy after advanced gastric cancer. METHODS: Seventy-five patients with advanced gastric cancer were divided into two groups: 30 patients with EAP regimen alone (control group), 45 patients with EAP chemotherapy and Shenmaiye group, and routine blood and liver function tests before and after chemotherapy. , Electrocardiogram, observation of gastrointestinal reactions and Karnofsky score. Results: The peripheral blood leukocytes, platelet reduction, electrocardiogram abnormalities, and gastrointestinal side effects were significantly lower in the chemotherapy and Shenmai group than in the chemotherapy control group (P < 0.01), while the Karnofsky score was significantly higher than that of the control group (P). <0 .0 5 ). Conclusion: Shenmai injection can significantly reduce and prevent myelosuppression, cardiotoxicity and digestive tract reactions induced by EAP regimen in postoperative adjuvant chemotherapy for advanced gastric cancer, thereby improving patient tolerance to chemotherapy side effects and quality of life during chemotherapy. .